August 22, 2012
The once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist Bydureon (exenatide), for which Eli Lilly Japan obtained approval in March, has been left unlisted in the NHI price list even now that the standard processing period (60-90 days since approval) has passed...read more